

Incidence of infections in pediatric patients using biological therapy

Incidencia de infecciones en pacientes pediátricos usuarios de terapia biológica

Supplementary Table 1. Incidence rates of infections according to biologic therapy

	Incidence rate per 100 person-years		
	General	First line	Second line
Anti-FNT-α			
<i>Adalimumab</i>	n = 76	n = 68	n = 8
Total infections	104.6 (IC 89.0-123.1)	87.8 (IC 72.9- 105.0)	266.7 (IC 185.5-371.9)
Non-serious infections	98.9 (IC 83.7-116.9)	82.6 (IC 66.7-97.5)	258.3 (IC 178.6-362.2)
Serious infections	5.7 (IC 2.6-10.9)	5.3 (IC 2.3-20.4)	8.3 (IC 4.1-41.1)
<i>Etanercept</i>	n = 38	n = 29	n = 9
Total infections	102.1 (IC 83.2-124.0)	115.6 (IC 93.3-141.6)	61.5 (IC 28.5-116.9)
Non-serious infections	97.8 (IC 79.4-119.4)	110.4 (IC 88.7-135.8)	61.5 (IC 28.5-116.9)
Serious infections	4.2 (IC 1.3-10.1)	5.1 (IC 0.1-12.5)	0
<i>Infliximab</i>	n = 8	n = 6	n = 2
Total infections	177.8 (IC 132.6-233.7)	188.0 (IC 139.7-247.9)	33.3 (IC 1.6-164.4)
Non-serious infections	151.9 (IC 110.4-204.0)	160.0 (IC 115.9-215.7)	33.3 (IC 1.6-164.4)
Serious infections	25.9 (IC 11.3-51.2)	28.0 (IC 12.2-55.3)	0
<i>Golimumab</i>	n=3	-	n = 3
Total infections	83.3 (IC 30.5-184.7)	-	83.3 (IC 30.5-184.7)
Non-serious infections	66.6 (IC 21.1-160.8)	-	66.6 (IC 21.1-160.8)
Serious infections	16.6 (IC 0.8-82.2)	-	16.6 (IC 0.8-82.2)
Anti CD20			
<i>Rituximab</i>	n = 10	n = 6	n = 4
Total infections	254.5 (IC 172.5-363.0)	385.7 (IC 259.4-553.4)	25 (IC 1.2-123.3)
Non-serious infections	236.4 (IC 157.7-341.4)	357.1 (IC 236.2-519.5)	25 (IC 1.2-123.3)
Serious infections	18.1 (IC 3.0-60.0)	28.5 (IC 4.7-94.4)	0
Inhibitor IL-6			
<i>Tocilizumab</i>	n = 29	n = 17	n = 12
Total infections	156.1 (IC 126.1-191.2)	150 (IC 117.6-188.7)	133.3 (IC 78.9-211.9)
Non-serious infections	136.8 (IC 108.9-169.9)	130.4 (IC 100.4-166.7)	133.3 (IC 78.9-211.9)
Serious infections	19.3 (IC 1.0-33.5)	19.5 (IC 9.5-35.9)	0
Inhibitor IL-2			
<i>Canakinumab</i>	n = 4	-	n = 4
Total infections	262.5 (IC 166.8-394.4)	-	262.5 (IC 166.8-394.4)
Non-serious infections	225.0 (IC 137.5-348.7)	-	225.0 (IC 137.5-348.7)
Serious infections	37.5 (IC 9.5-102.1)	-	37.5 (IC 9.5-102.1)
Inhibitor T cells co-stimulation (CTLA 4-Ig)			
<i>Abatacept</i>	n = 5	n = 3	n = 2
Total infections	266.7 (IC 123.8-506.4)	400.0 (IC 185.8-759.6)	0
Non-serious infections	266.7 (IC 123.8-506.4)	400.0 (IC 185.8-759.6)	0
Serious infections	0	0	0

n: number of individuals, Anti-TNF: anti-tumor necrosis factor, IL-6: interleukin 6, IL-2: interleukin 2.